Pediatric sarcomas: challenges and opportunities
Yuan Gao, Kelly M. Bailey, Samuel C. Blackman, John H. Bushweller, Shasha Chong, Kevin DeHond, Jolanta Grembecka, Mark E. Hatley, Cigall Kadoch, Angela N. Koehler, Corinne M. Linardic, Phil Renna, Frederic J. Reu, Miguel N. Rivera, Elizabeth A. Stewart, Bruce Stillman, E. Alejandro Sweet-Cordero, Kimberly Stegmaier, Christopher R. Vakoc, Lillian M. GuentherPediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancements in research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.